Prescription Drugs 2 Go

J Clin Hypertens (Greenwich). © 2010 Wiley Periodicals, Inc. Hypertensive patients with cardiovascular (CV) comorbidities are at increased risk, and cardiologists’ care should put particular emphasis on controlling blood pressure. Data on blood pressure treatment and control and drug utilization on a global scale, however, are scarce. Aiming to resolve this lack of information, the authors analyzed the data of International Survey Evaluating Microalbuminuria Routinely by Cardiologists in Patients With Hypertension (i-SEARCH) to gain further insights into national and regional blood pressure control and antihypertensive pharmacotherapy prescribed in cardiology practice. …

Results from a Dutch study suggest that treatment with Beta Blockers reduces the risk for mortality and exacerbations among patients with chronic obstructive pulmonary disease. (Source: MedWire News – Respiratory)

Patients with chronic obstructive pulmonary disease (COPD) may have fewer respiratory flare-ups and longer survival if they take beta-blocker medications, according to a report in the May 24 issue of Archives of Internal Medicine, one of the JAMA/Archives journals. By the year 2020, COPD-a diagnosis that includes emphysema and chronic bronchitis-is expected to become the third leading cause of death in the Western world, according to background information in the article. Patients with the condition are also prone to develop and die from cardiovascular diseases… (Source: Health News from …

Conclusion: This study confirms that RT patients are at high risk of SC. The use of ACEi or ARBs is associated with an approximately two-fold reduced risk of Keratinocyte cancers compared to non users in RT recipients. We did not observe an association between the incidence of SC and the use of other classes of antihypertensive drugs. Any chemoprotective effect of these agents may reflect inhibition of the growth factor activity of angiotensin II. Use of ACEi or ARBs, when this is possible, should be considered in RT patients with …

Patients with chronic obstructive pulmonary disease may have fewer respiratory flare-ups and may survive longer if they take beta-blockers, research has found. (Source: Nursing Times Breaking News)

MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising.

Patients with chronic obstructive pulmonary disease may have fewer respiratory flare-ups and longer survival if they take beta-blocker medications, according to a new report. (Source: ScienceDaily Headlines)

Patients with chronic obstructive pulmonary disease (COPD) had about a 30% reduction in deaths and disease exacerbations when treated with beta-blockers, data from a large cohort study showed. (Source: MedPage Today Allergy)

(Source: Physician’s First Watch current issue)

Beta-blocker treatment lowers the risk for exacerbations and improves survival in patients with chronic obstructive pulmonary disease, perhaps because of dual cardiopulmonary protective properties. Medscape Medical News (Source: Medscape Today Headlines)

MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising.

Improved survival and reduced exacerbations without respiratory riskRelated items from OnMedicaSystolic blood pressure should be sole measure of hypertensionBenefits of statins far outweigh diabetes riskPrimary care criticised over retinopathy failingsType 2 diabetes – shock toll on South Asian children Fat-busting drug available over-the-counter (Source: OnMedica Latest News)